MYOMO CMO sells 32,000 shares around $1

Rhea-AI Filing Summary

MYOMO, INC. Chief Medical Officer Harry Kovelman reported open-market sales of company common stock over two days. He sold 20,464 shares on May 27, 2026 at a weighted average price of $1.002 per share and 11,536 shares on May 28, 2026 at a weighted average price of $1.0172 per share. After these transactions, he continued to hold 108,618 shares directly.

Insider Trade Summary

Net Seller: 32,000 shares

Net Sell 2 txns

Insider Kovelman Harry

Role Chief Medical Officer

Sold 32,000 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	11,536	$1.0172	$12K
Sale	Common Stock	20,464	$1.002	$21K

Holdings After Transaction: Common Stock — 108,618 shares (Direct)

Footnotes (3)

1. F1. Represents open market sale of shares.
2. F2. Represents weighted average sales price. Shares were sold in multiple lots at prices ranging from $1.00 to $1.005 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.
3. F3. Represents weighted average sales price. Shares were sold in multiple lots at prices ranging from $1.00 to $1.035 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

Key Figures

Shares sold May 27, 2026: 20,464 shares Shares sold May 28, 2026: 11,536 shares Total shares sold: 32,000 shares +1 more

4 metrics

Shares sold May 27, 2026 20,464 shares Open-market sale of common stock at $1.002 average price

Shares sold May 28, 2026 11,536 shares Open-market sale of common stock at $1.0172 average price

Total shares sold 32,000 shares Combined open-market sales over two consecutive trading days

Shares held after transactions 108,618 shares Direct ownership following the reported sales

Key Terms

open-market sale, weighted average sales price, multiple lots

3 terms

open-market sale financial

"Represents open market sale of shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sales price financial

"Represents weighted average sales price. Shares were sold in multiple lots..."

multiple lots financial

"Shares were sold in multiple lots at prices ranging from $1.00 to $1.005 per share."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MYOMO (MYO) disclose for Harry Kovelman?

MYOMO’s Chief Medical Officer, Harry Kovelman, disclosed open-market sales of company common stock. He sold a total of 32,000 shares over two days at weighted average prices around $1 per share, while remaining directly invested with 108,618 shares held after the transactions.

How many MYOMO (MYO) shares did Harry Kovelman sell and on which dates?

Harry Kovelman sold 20,464 MYOMO shares on May 27, 2026 and 11,536 shares on May 28, 2026. Both transactions were reported as open-market sales of common stock at weighted average prices slightly above $1 per share.

What prices were received in Harry Kovelman’s MYOMO (MYO) stock sales?

The sales used weighted average prices. On May 27, 2026, shares were sold at an average of $1.002, in multiple lots from $1.00 to $1.005. On May 28, 2026, the average was $1.0172, with lots ranging from $1.00 to $1.035.

How many MYOMO (MYO) shares does Harry Kovelman hold after these sales?

Following the reported open-market transactions, Harry Kovelman holds 108,618 shares of MYOMO common stock directly. This post-transaction figure reflects his remaining ownership after selling a combined 32,000 shares across two consecutive trading days.

Were Harry Kovelman’s MYOMO (MYO) stock sales executed in multiple lots?

Yes. Footnotes state the reported prices are weighted averages. On both trading days, his MYOMO shares were sold in multiple lots within narrow price ranges around $1 per share, and detailed lot-by-lot information is available to regulators upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/28/2026 - 09:53 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kovelman Harry

(Last) (First) (Middle)

C/O MYOMO, INC.

45 BLUE SKY DR., SUITE 101

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/27/2026		S		20,464(1)	D	$1.002(2)	120,154	D
Common Stock	05/28/2026		S		11,536(1)	D	$1.0172(3)	108,618	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents open market sale of shares.

2. Represents weighted average sales price. Shares were sold in multiple lots at prices ranging from $1.00 to $1.005 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

3. Represents weighted average sales price. Shares were sold in multiple lots at prices ranging from $1.00 to $1.035 per share. Reporting party agrees to provide details of the transactions to the SEC upon request.

	/s/ David A. Henry, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)